000064325 001__ 64325
000064325 005__ 20190709135631.0
000064325 0247_ $$2doi$$a10.1177/1010428317728285
000064325 0248_ $$2sideral$$a103636
000064325 037__ $$aART-2017-103636
000064325 041__ $$aeng
000064325 100__ $$aCaresia Aroztegui, A.P.
000064325 245__ $$a18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging
000064325 260__ $$c2017
000064325 5060_ $$aAccess copy available to the general public$$fUnrestricted
000064325 5203_ $$aCurrent guidelines do not systematically recommend 18F-FDG PET/CT for breast cancer staging; and the recommendations and level of evidence supporting its use in different groups of patients vary among guidelines. This review summarizes the evidence about the role of 18F-FDG PET/CT in breast cancer staging and the therapeutic and prognostic impact accumulated in the last decade. Other related aspects, such as the association of metabolic information with biology and prognosis are considered and evidence-based recommendations for the use of 18F-FDG PET/CT in breast cancer staging are offered. We systematically searched MEDLINE for articles reporting studies with at least 30 patients related to clinical questions following the Problem/Population, Intervention, Comparison, and Outcome framework. We critically reviewed the selected articles and elaborated evidence tables structuring the summarized information into methodology, results, and limitations. The level of evidence and the grades of recommendation for the use of 18F-FDG PET/CT in different contexts are summarized. Level III evidence supports the use of 18F-FDG PET/CT for initial staging in patients with recently diagnosed breast cancer; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a weak recommendation in this population. In patients with locally advanced breast cancer, level II evidence supports the use of 18F-FDG PET/CT for initial staging; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a strong recommendation in this population. In patients with recently diagnosed breast cancer, the metabolic information from baseline 18F-FDG PET/CT is associated with tumor biology and has prognostic implications, supported by level II evidence. In conclusion, 18F-FDG PET/CT is not recommended for staging all patients with early breast cancer, although evidence of improved regional and systemic staging supports its use in locally advanced breast cancer. Baseline tumor glycolytic activity is associated with tumor biology and prognosis.
000064325 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000064325 592__ $$a1.149$$b2017
000064325 593__ $$aMedicine (miscellaneous)$$c2017$$dQ1
000064325 593__ $$aCancer Research$$c2017$$dQ2
000064325 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000064325 700__ $$aGarcía Vicente, A.M.
000064325 700__ $$aAlvarez Ruiz, S.$$uUniversidad de Zaragoza
000064325 700__ $$aDelgado Bolton, R.C.
000064325 700__ $$aOrcajo Rincon, J.
000064325 700__ $$aGarcia Garzon, J.R.
000064325 700__ $$ade Arcocha Torres, M.
000064325 700__ $$aGarcia-Velloso, M.J.
000064325 7102_ $$11010$$2770$$aUniversidad de Zaragoza$$bDpto. Pediatría Radiol.Med.Fís$$cÁrea Radiol. y Medicina Física
000064325 773__ $$g39, 10 (2017), 1-23$$pTumor biol.$$tTUMOR BIOLOGY$$x1010-4283
000064325 8564_ $$s143547$$uhttps://zaguan.unizar.es/record/64325/files/texto_completo.pdf$$yVersión publicada
000064325 8564_ $$s107869$$uhttps://zaguan.unizar.es/record/64325/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000064325 909CO $$ooai:zaguan.unizar.es:64325$$particulos$$pdriver
000064325 951__ $$a2019-07-09-12:33:13
000064325 980__ $$aARTICLE